Effect of Bulky N -Dibenzofuranylmethyl Substitution on the 5-HT 2 Receptor Affinity and Efficacy of a Psychedelic Phenethylamine.
Breno A SoaresThirumal YempalaDarío Martínez-AfaniWilliams Acevedo-FuentesJosé BreaMaria Isabel LozaMarta CimadevilaBruce K CasselsPublished in: ACS chemical neuroscience (2024)
The introduction of arylmethyl substituents on the amine nitrogen atom of phenethylamines and tryptamines often results in profound increases in their affinity and functional activity at 5-HT 2 serotonin receptors. To probe the sensitivity of this effect to substantially larger N -substituents, ten derivatives of the well-characterized psychedelic phenethylamine 2C-B were prepared by appending different dibenzo[ b , d ]furylmethyl (DBFM) moieties to the basic nitrogen. The DBFM group attached to the amino group through its 1-, -2-, or 3-position decreased affinity and agonist activity at the 5-HT 2A/2C receptors. Substitution through the 4-position usually favored affinity for all three 5-HT 2 receptor subtypes with compound 5 exhibiting 10- and 40-fold higher affinities at the 5-HT 2A and 5-HT 2C receptors, respectively, but less than fourfold selectivity among the three receptor subtypes. Nevertheless, all were relatively weak partial 5-HT 2A R agonists, mostly in the low micromolar range, but full or nearly full agonists at the 5-HT 2C subtype as determined in a calcium mobilization assay. Molecular docking simulations suggested that the dibenzofuryl portion dives more deeply into the orthosteric binding site of the 5-HT 2A than the 5-HT 2C receptor, interacting with the Trp336 6.48 toggle switch associated with its activation, while the phenylamine moiety lies close to the extracellular side of the receptor. In conclusion, a very bulky N -substituent on a phenethylamine 5-HT 2 receptor agonist is tolerated and may increase affinity if its orientation is appropriate. However, the G q protein-mediated potencies are generally low, with low efficacy (relative to 5-HT) at the 5-HT 2A receptor, somewhat higher efficacy at the 5-HT 2B subtype, and full or nearly full efficacy at the 5-HT 2C subtype.